Mondo Visione Worldwide Financial Markets Intelligence

FTSE Mondo Visione Exchanges Index:

News Centre

  • DSB Publishes Final Report From UPI Legal Terms And Conditions Consultation

    Date 12/04/2022

    The Derivatives Service Bureau (DSB), founded by the Association of National Numbering Agencies (ANNA) to facilitate the allocation and maintenance of ISINs, CFIs and FISNs for OTC derivatives, and subsequently designated by the FSB as the sole Unique Product Identifier (UPI) Service Provider to facilitate creation and distribution of UPIs globally, has announced today the publication of the UPI Legal Terms and Conditions Consultation Final Report and draft user legal documentation. 

  • FinClear Announces Unlisted Liquidity Venue: FCX - FCX Is Live As A Digital Registry For Unlisted Companies. Capital Raising Tools Will Be Added This Year And A Fully Licensed Liquidity Venue Opened In 2023.

    Date 12/04/2022

    FinClear, the Australian financial services and technology company, today announced the launch of a new digital facility for unlisted securities, FCX.

  • Circular On Self-Regulatory Measures Taken By CFFEX In March 2022

    Date 12/04/2022

    To prevent market risks, maintain the orderly operation of the market and protect investors’ legitimate rights and interests, China Financial Futures Exchange (CFFEX) took the following self-regulatory measures against violations of exchange rules in March 2022.

  • Hong Kong Securities And Futures Commission Bans Poon Choi Yung For 20 Months

    Date 12/04/2022

    The Securities and Futures Commission (SFC) has banned Mr Poon Choi Yung, a former licensed representative of China Tonghai Securities Limited, from re-entering the industry for 20 months from 12 April 2022 to 11 December 2023 for breaches of the SFC’s Code of Conduct.

  • Shanghai Stock Exchange STAR Market Biomedicine Index To Be Released Soon

    Date 12/04/2022

    The “14th Five-year Plan” period has seen the accelerated formation of a new development paradigm featuring dual circulation, in which the domestic economic cycle plays a leading role while the international economic cycle remains its extension and supplement, and China’s biomedical market has ushered in a stage of high-quality development. Meanwhile, the new development stage has higher requirements on the biomedical industry, which finds it urgent to expedite the innovation-driven transformation so as to bolster the creation of the new development paradigm. Today, the Shanghai Stock Exchange (SSE) and the China Securities Index Co., Ltd. (CSI) officially announced the relevant arrangements for the release of the SSE STAR Market Biomedicine Index ( the STAR Market Biomedicine Index for short). After the screening for liquidity, the STAR Market Biomedicine Index is to include the stocks of 50 companies with large market capitalization in the biomedicine, biomedical engineering and other biological industries as index constituents. The 5 stocks with the largest weights are Shanghai Junshi Biosciences Co., Ltd., Zhejiang Orient Gene Biotech Co., Ltd., Cansino Biologics Inc., Shanghai Medicilon Inc. and Qingdao Haier Biomedical Co., Ltd., with a combined weight of 33%.